中文速读
本研究针对胰腺导管腺癌(PDAC),用SLC6A14敲除/过表达的PDAC细胞(T3M4、KPC)及小鼠皮下/原位移植瘤模型,借助Envirus慢病毒增强试剂进行慢病毒转染构建稳定细胞系,发现SLC6A14通过氨基酸竞争性摄取塑造免疫抑制微环境并促进肿瘤进展。
小鼠肿瘤胰质粒DNAT3M4KPCPanc02
Targeting SLC6A14-mediated nutrient competition reverses an immunosuppressive metabolic niche in pancreatic cancer.
Affiliations
- 1 Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, 310000, Zhejiang, China.
- 2 Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
- 3 Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.
- 4 MOE Joint International Research Laboratory of Pancreatic Diseases, Hangzhou, Zhejiang, China.
- 5 Institute of Translational Medicine, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
- 6 Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, 310000, Zhejiang, China. shirleybai@zju.edu.cn.
- 7 Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. shirleybai@zju.edu.cn.
- 8 Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China. shirleybai@zju.edu.cn.
- 9 MOE Joint International Research Laboratory of Pancreatic Diseases, Hangzhou, Zhejiang, China. shirleybai@zju.edu.cn.
- PMID: 42963794
- DOI: 10.1186/s40164-026-00818-9
Abstract
Pancreatic ductal adenocarcinoma (PDAC) exhibits an immunosuppressive and nutrient-deficient tumor microenvironment (TME), where solute carrier (SLC) transporters are critical in metabolic reprogramming and intercellular communication. However, the precise mechanisms by which specific SLCs contribute to therapeutic resistance through the TME remain unclear. We integrated transcriptomic data from clinical cohorts with computational analysis and expression validation to identify the SLC family members most closely linked to PDAC patient outcomes. Using in vitro and in vivo experiments along with multi‑omics approaches, we further clarified its functional roles in stromal-immune-metabolic networks within the TME. Following virtual screening of a million‑compound library and validated by binding assays, two target‑specific inhibitors were identified. Using pharmacological and genetic methods, the therapeutic potential of targeting this pathway was systematically evaluated. SLC6A14 is identified as a prognostic biomarker and functional driver of PDAC progression, with higher expression levels correlating with poor patient outcomes; it facilitates tumor growth by modifying amino acid metabolic reprogramming and exerting immunosuppressive effects by competitively impairing amino acid uptake in dendritic cells and CD8⁺ T cells. STOCK1N-75990 is a specific SLC6A14 inhibitor that competitively blocks amino acid binding, induces intracellular nutrient deprivation, and causes profound metabolic collapse; it exhibits marked anti-tumor activity and limited toxicity in preclinical models, synergizing with anti-PD1 therapy. These findings establish SLC6A14 as a potent multifunctional therapeutic target and demonstrate the clinical relevance of its inhibitors as a metabolic immunotherapy for PDAC.
https://doi.org/10.1186/s40164-026-00818-9
其他病毒和革兰式阴性菌增强试剂Envirus™ 已有 23 篇已发表文献
同类研究
- Cytotechnology. 2024 Dec 1;77(1):10.doi: 10.1007/s10616-024-00671-w. KDM1A-mediated ZFP64 demethylation activates CENPL…
- Cell Rep Med. 2024 Oct 15;5(10):101731.doi: 10.1016/j.xcrm.2024.101731. Epub 2024 Sep 19. Reprograming immunosuppressive…
- Biomed Res Int. 2022 Jul 12;2022:7850658.doi: 10.1155/2022/7850658. eCollection 2022. SLC6A14 Depletion Contributes to A…
- Inflammation.2020 Dec;43(6):2061-2074.doi: 10.1007/s10753-020-01274-1.Cyclin-Dependent Kinase 9 Inhibition Suppresses Ne…
- Cell Transplant.2019 Dec;28(12):1614-1623.doi: 10.1177/0963689719875409 A circular RNA derived from MMP9 facilitates ora…